Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Malignant Solid Neoplasm 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 38Radiotherapy 22Radiosurgery 22Radiation 11Magnetic Resonance Spectroscopy 11Irinotecan 11Cyclophosphamide 11Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9pembrolizumab 8Filgrastim 8Carboplatin 8Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5cediranib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × Ferrosoferric Oxide × Clear all
NCT00769093 2017-04-21

Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy

OHSU Knight Cancer Institute

Phase 1 Terminated
6 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡